The Frequency of Certain Genetic Polymorphisms and Their Influence on the Therapeutic Response of Patients Treated with Olanzapine Cover

.blurhash-client-img { display: none !important; }

The Frequency of Certain Genetic Polymorphisms and Their Influence on the Therapeutic Response of Patients Treated with Olanzapine

EABR. Experimental and Applied Biomedical Research

By: Sasa Babic, Milena Stojkovic, Elvis Mahmutovic, Teodora Safiye, Sladjana Veselinovic, Milan Djordjic, Petar Canovic, Olivera Radmanovic, Vladimir Gavrilovic, Maida Burdzovic and Branimir Radmanovic

Open Access

|Dec 2024

Figures & Tables

Frequency of FMO3 alleles and genotypes in patients on olanzapine therapy

Variation		Observed frequency
Alleles
rs2266782 (15167G>A, E158K)
15167A		0.371 (89/240)
rs1736557 (18281G>A, V257M)
18281A		0.021 (5/240)
rs2266780 (21443A>G, E308G)
21443G		0.146 (35/240)
Genotypes
rs2266782 (15167G>A, E158K)
	GG	0.400 (48/120)
	GA	0.458 (55/120)
	AA	0.142 (17/120)
rs1736557 (18281G>A, V257M)
	GG	0.958 (115/120)
	GA	0.042 (5/120)
	AA	0.000 (0/120)
rs2266780 (21443A>G, E308G)
	AA	0.725 (87/120)
	AG	0.258 (31/120)
	GG	0.017 (2/120)

Influence of the FMO3 E308G genotype variation on the therapeutic response measured by the PANSS scale

E308G
PANSS_delta
Variation	N	Mean	Standard Deviation	Minimum	Maximum	ANOVA, df, p
0	87	15.3	4.5	2.0	25.0	0.2, 2, 0.819
1	31	15.1	5.1	3.8	23.9
2	2	13.3	4.5	10.1	16.5
Total	120	15.2	4.7	2.0	25.0

Frequency of CYP1A2 alleles and genotypes in patients on olanzapine therapy

Alleles, frequency, 95% confidence interval
rs2069514 (−3860G>A, CYP1A21C*)
−3860A		0.000 (0/240)	0.000; 0.020
rs762551 (−163C>A, CYP1A21F*)
−163A		0.658 (158/240)	0.596; 0.715
rs2472297 (74735539C>T, CYP1A1/1A2)
74735539T		0.154 (37/240)	0.114; 0.206
Genotypes
rs2069514 (−3860G>A, CYP1A21C*)
	GG	1.000 (120/120)	0.962; 1.006
	GA	0.000 (0/120)	0.000; 0.038
	AA	0.000 (0/120)	0.000; 0.038
rs762551 (−163C>A, CYP1A21F*)
	CC	0.108 (13/120)	0.064; 0.178
	CA	0.467 (56/120)	0.380; 0.556
	AA	0.425 (51/120)	0.340; 0.514
rs2472297 (74735539C>T, CYP1A1/1A2)
	CC	0.717 (86/120)	0.630; 0.790
	CT	0.258 (31/120)	0.188; 0.344
	TT	0.025 (3/120)	0.006; 0.075

Influence of CYP1A2 A1/A2 genotype variation on therapeutic response measured by the PANSS scale

CYP1A2 A1/A2
PANSS_delta
Variation	N	Mean	Standard Deviation	Minimum	Maximum	ANOVA, df, p
0	86	15.3	4.8	2.0	25.0	0.4, 2, 0.691
1	31	15.1	4.5	5.3	23.9
2	3	13.0	4.8	7.7	17.2
Total	120	15.2	4.7	2.0	25.0

Effect of FMO3 E158K genotype variation on therapeutic response measured by the PANSS scale

E158K
PANSS_delta
Variation	N	Mean	Standard Deviation	Minimum	Maximum	ANOVA, df, p
0	48	15.0	4.6	5.7	25.0	0.5, 2, 0.608
1	55	15.7	4.5	3.7	23.9
2	17	14.5	5.6	2.0	21.1
Total	120	15.2	4.7	2.0	25.0

Effect of FMO3 V257M genotype variation on therapeutic response measured by the PANSS scale

V257M
PANSS_delta
Variation	N	Mean	Standard Deviation	Minimum	Maximum	ANOVA, df, p
0	115	15.2	4.6	2.0	25.0	0.2, 2, 0.797
1	4	16.6	6.7	7.7	22.1
2	1	16.7	n.a.	16.7	16.7
Total	120	15.2	4.6	2.1	25.0

Influence of UG1A4*2 genotype variation on therapeutic response measured by the PANSS scale

UG1A4*2
UG1A4		N	Mean	Standard Deviation	T-test, df, p
PANSS_delta	0	112	15.1	4.7	0.8, 118, 0.418
PANSS_delta	1	8	16.5	3.6	0.8, 118, 0.418

Influence of CYP2D6*6 genotype variation on therapeutic response measured by the PANSS scale

CYP2D66*
PANSS_delta
Variation	N	Mean	Standard Deviation	Minimum	Maximum	ANOVA, df, p
0	116	15.2	4.7	2.0	25.0	1.1, 2, 0.317
1	3	13.2	3.5	10.3	17.2
2	1	21.4	n.a.	21.4	21.4
Total	120	15.2	4.7	2.0	25.0

Influence of CYP1A2*1F genotype variation on therapeutic response measured by the PANSS scale

CYP1A21F*
PANSS_delta
Variation	N	Mean	Standard Deviation	Minimum	Maximum	ANOVA, df, p
0	14	14.8	4.3	6.3	22.2	0.1, 2, 0.920
1	55	15.3	4.7	2.0	23.8
2	51	15.3	4.8	3.7	25.0
Total	120	15.2	4.7	2.0	25.0

Influence of CYP2D6*4 genotype variation on therapeutic response measured by the PANSS scale

CYP2D64*
PANSS_delta
Variation	N	Mean	Standard Deviation	Minimum	Maximum	ANOVA, df, p
0	77	15.0	4.8	2.0	23.9	0.6, 2, 0.549
1	40	15.4	4.6	5.3	25.0
2	3	17.9	2.3	16.5	20.6
Total	120	15.2	4.7	2.0	25.0

Frequency of UGT1A4 alleles and genotypes in patients on olanzapine therapy

Variation	Frequency	95% Confidence Interval
Alleles
rs6755571 (70C>A, UGT1A42*)
70A	0.033 (8/240)	0.016; 0.066
Genotypes
rs6755571 (70C>A, UGT1A42*)
CC	0.933 (112/120)	0.871; 0.967
CA	0.067 (58/120)	0.033; 0.129
AA	0.000 (0/120)	0.000; 0.038

Frequency of CYP2D6 alleles and genotypes in patients on olanzapine therapy

Variation		Observed frequency
Alleles
rs35742686 (2549delA, CYP2D63*)
2549delA		0.0080 (2/240)
rs3892097 (1846G>A, CYP2D64*)
1846A		0.188 (45/240)
rs5030655 (1707delT, CYP2D66*)
1707delT		0.021 (5/240)
Genotypes
rs35742686 (2549delA, CYP2D63*)
	AA	0.975 (117/120)
	A delA	0.017 (2/120)
	delA delA	0.000 (0/120)
rs3892097 (1846G>A, CYP2D6*4)
	GG	0.650 (78/120)
	GA	0.3257 (39/120)
	AA	0.025 (31/120)
rs5030655 (1707delT, CYP2D66*)
	TT	0.942 (113/120)
	T delT	0.025 (3/120)
	delT delT	0.008 (1/120)

Influence of CYP2D6*3 genotype variation on therapeutic response measured by the PANSS scale

CYP2D63*
PANSS_delta
CYP2D6*3		N	Mean	Standard Deviation	T-test, df, p
PANSS_delta	0	118	15.2	4.7	0.67, 118, 0.504
PANSS_delta	1	2	17.4	1.3	0.67, 118, 0.504

DOI: https://doi.org/10.2478/eabr-2024-0018 | Journal eISSN: 2956-2090 | Journal ISSN: 2956-0454

Journal RSS Feed

Language: English

Submitted on: May 1, 2024

Accepted on: Oct 16, 2024

Published on: Dec 17, 2024

Published by: University of Kragujevac, Faculty of Medical Sciences

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

genetic polymorphism,

Related subjects:

Clinical medicine,

Clinical medicine, other

© 2024 Sasa Babic, Milena Stojkovic, Elvis Mahmutovic, Teodora Safiye, Sladjana Veselinovic, Milan Djordjic, Petar Canovic, Olivera Radmanovic, Vladimir Gavrilovic, Maida Burdzovic, Branimir Radmanovic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.